Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Defining and recognising locally advanced basal cell carcinoma.
Amici JM, Battistella M, Beylot-Barry M, Chatellier A, Dalac-Ra S, Dreno B, Falandry C, Froget N, Giacchero D, Grob JJ, Guerreschir P, Leccia MT, Malard O, Mortier L, Routier E, Stefan A, Stefan D, Stoebner PE, Basset-Seguin N. Amici JM, et al. Among authors: mortier l. Eur J Dermatol. 2015 Nov-Dec;25(6):586-94. doi: 10.1684/ejd.2015.2641. Eur J Dermatol. 2015. PMID: 26574792 Review.
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Williams S, Fittipaldo A, Xynos I, Hansson J. Basset-Seguin N, et al. Among authors: mortier l. Lancet Oncol. 2015 Jun;16(6):729-36. doi: 10.1016/S1470-2045(15)70198-1. Epub 2015 May 13. Lancet Oncol. 2015. PMID: 25981813 Clinical Trial.
[Items that justify a day-care hospital stay for the management of skin cancer. Guidelines from the Oncodermatology Group of the Société Française de Dermatologie].
Mortier L, Saiag P, Thomas L, Lebbe C, Maubec E, Meyer N, Jouary T, Dalac S, Lesimple T, Dreno B, Richard MA, Leccia MT; groupe de cancérologie de la Société française de dermatologie. Mortier L, et al. Ann Dermatol Venereol. 2016 Aug-Sep;143(8-9):559-61. doi: 10.1016/j.annder.2016.02.031. Epub 2016 Jun 27. Ann Dermatol Venereol. 2016. PMID: 27364897 French. No abstract available.
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A; ERIVANCE BCC Investigators. Sekulic A, et al. Among authors: mortier l. BMC Cancer. 2017 May 16;17(1):332. doi: 10.1186/s12885-017-3286-5. BMC Cancer. 2017. PMID: 28511673 Free PMC article. Clinical Trial.
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Arenberger P, Fife K, Raimundo A, Dika E, Dimier N, Fittipaldo A, Xynos I, Hansson J. Basset-Séguin N, et al. Among authors: mortier l. Eur J Cancer. 2017 Nov;86:334-348. doi: 10.1016/j.ejca.2017.08.022. Epub 2017 Nov 5. Eur J Cancer. 2017. PMID: 29073584 Free article. Clinical Trial.
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type.
Beylot-Barry M, Mermin D, Maillard A, Bouabdallah R, Bonnet N, Duval-Modeste AB, Mortier L, Ingen-Housz-Oro S, Ram-Wolff C, Barete S, Dalle S, Maubec E, Quereux G, Templier I, Bagot M, Grange F, Joly P, Vergier B, Vially PJ, Gros A, Pham-Ledard A, Frison E, Merlio JP. Beylot-Barry M, et al. Among authors: mortier l. J Invest Dermatol. 2018 Sep;138(9):1982-1989. doi: 10.1016/j.jid.2018.03.1516. Epub 2018 Mar 27. J Invest Dermatol. 2018. PMID: 29596904 Free article. Clinical Trial.
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.
Kandel M, Allayous C, Dalle S, Mortier L, Dalac S, Dutriaux C, Leccia MT, Guillot B, Saiag P, Lacour JP, Legoupil D, Lesimple T, Aubin F, Beylot-Barry M, Brunet-Possenti F, Arnault JP, Granel-Brocard F, Stoebner PE, Dupuy A, Maubec E, Grob JJ, Dreno B, Rotolo F, Ballon A, Michiels S, Lebbe C, Borget I. Kandel M, et al. Among authors: mortier l. Eur J Cancer. 2018 Dec;105:33-40. doi: 10.1016/j.ejca.2018.09.026. Epub 2018 Oct 29. Eur J Cancer. 2018. PMID: 30384014
315 results